NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination -January 17, 2024 at 06:49 am EST

RADNOR, Pa., Jan. 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and PTSD, today...

Related Keywords

France ,French ,Stephen Willard ,Nasdaq Hearings Panel The ,Us National Institutes Of Health ,Nasdaq ,Alvogen Pharmaceuticals ,Nrx Pharmaceuticals ,Source Nrx Pharmaceuticals ,Prnewswire Nrx Pharmaceuticals Inc ,Nasdaq Stock Market ,Nrx Pharmaceuticals Inc ,Nasdaq Hearings Panel ,Nasdaq Capital Market ,Capital Market ,Corporate Presentation ,New Drug Application ,Breakthrough Therapy ,Fast Track Designation ,Securities Litigation Reform Act ,Markets ,